AGIO:NASDAQ
Agios Pharmaceuticals Inc
27,68 $
arrow_upward
+4,41%(+1,17) 1D
27,68 $
0,00% (0,00)
bedtimeAfter hours
Closed: 3 հնս, 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
26,51 $
High
27,75 $
Low
26,49 $
Mkt. cap
1,65 մլրդ
Avg. vol.
1,02 մլն
Volume
19,00
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,25 $
Beta
0,59
Shares outstanding
59,47 մլն
No. of employees
540
Open
26,51 $
High
27,75 $
Low
26,49 $
Mkt. cap
1,65 մլրդ
Avg. vol.
1,02 մլն
Volume
19,00
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,25 $
Beta
0,59
Shares outstanding
59,47 մլն
No. of employees
540
Analyst outlook
Analyst Ratings
Based on 8 analysts giving stock ratings to AGIO in the past 3 months
Buy
Buy
5
Hold
3
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for AGIO in the last 3 months.
Highest
Current 27,68 $
50,00 $ (+80,64%)
Average
39,20 $ (+41,62%)
Lowest
28,00 $ (+1,16%)
News stories
From sources across the web
Investing.com
·
3 օր առաջ
Agios licenses oral SYK inhibitor for rare blood disorder
Stock Titan
·
3 օր առաջ
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
AI content may include mistakes. Learn more